Trishul Siddharthan1,2, Suzanne L Pollard3,4, Peter Jackson5, Nicole M Robertson3,4, Adaeze C Wosu4,6, Nihaal Rahman3,4, Roma Padalkar3,4, Isaac Sekitoleko7, Esther Namazzi7, Patricia Alupo7, John R Hurst8, Robert Kalyesubula9,10, David Dowdy6, Robert Wise3,4, Peter J Barnes11, William Checkley3,4, Bruce Kirenga7. 1. Division of Pulmonary and Critical Care, University of Miami, School of Medicine, Johns Hopkins University, 1951 NW 7th Ave, Suite 2308, Miami, FL, 33136, USA. tsiddhar@miami.edu. 2. Center for Global Non-Communicable Diseases, Johns Hopkins University, Baltimore, USA. tsiddhar@miami.edu. 3. Division of Pulmonary and Critical Care, University of Miami, School of Medicine, Johns Hopkins University, 1951 NW 7th Ave, Suite 2308, Miami, FL, 33136, USA. 4. Center for Global Non-Communicable Diseases, Johns Hopkins University, Baltimore, USA. 5. Division of Pulmonary and Critical Care, Virginia Commonwealth University, Richmond, USA. 6. Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, USA. 7. Makerere University Lung Institute, Makerere College of Health Sciences, Kampala, Uganda. 8. UCL Respiratory, University College London, London, UK. 9. Department of Physiology, Makerere College of Health Sciences, Kampala, Uganda. 10. African Community Center for Social Sustainability, Nakaseke, Uganda. 11. National Health and Lung Institute, Imperial College, London, UK.
Abstract
BACKGROUND: COPD is a leading cause of death globally, with the majority of morbidity and mortality occurring in low- and middle-income country (LMIC) settings. While tobacco-smoke exposure is the most important risk factor for COPD in high-income settings, household air pollution from biomass smoke combustion is a leading risk factor for COPD in LMICs. Despite the high burden of biomass smoke-related COPD, few studies have evaluated the efficacy of pharmacotherapy in this context. Currently recommended inhaler-based therapy for COPD is neither available nor affordable in most resource-limited settings. Low-dose theophylline is an oral, once-a-day therapy, long used in high-income countries (HICs), which has been proposed for the management of COPD in LMICs in the absence of inhaled steroids and/or bronchodilators. The Low-dose Theophylline for the Management of Biomass-Associated COPD (LODOT-BCOPD) trial investigates the clinical efficacy and cost-effectiveness of low-dose theophylline for the management of biomass-related COPD in a low-income setting. METHODS: LODOT-BCOPD is a randomized, double-blind, placebo-controlled trial to test the efficacy of low-dose theophylline in improving respiratory symptoms in 110 participants with moderate to severe COPD in Central Uganda. The inclusion criteria are as follows: (1) age 40 to 80 years, (2) full-time resident of the study area, (3) daily biomass exposure, (4) post-bronchodilator FEV1/FVC below the 5th percentile of the Global Lung Initiative mixed ethnic reference population, and (5) GOLD Grade B-D COPD. Participants will be randomly assigned to receive once daily low-dose theophylline (200 mg ER, Unicontin-E) or placebo for 52 weeks. All participants will receive education about self-management of COPD and rescue salbutamol inhalers. We will measure health status using the St. George's Respiratory Questionnaire (SGRQ) and quality of life using the EuroQol-5D (EQ-5D) at baseline and every 6 months. In addition, we will assess household air pollution levels, serum inflammatory biomarkers (fibrinogen, hs-CRP), and theophylline levels at baseline, 1 month, and 6 months. The primary outcome is change in SGRQ score at 12 months. Lastly, we will assess the cost-effectiveness of the intervention by calculating quality-adjusted life years (QALYs) from the EQ-5D. TRIAL REGISTRATION: ClinicalTrials.gov NCT03984188 . Registered on June 12, 2019 TRIAL ACRONYM: Low-dose Theophylline for the Management of Biomass-Associated COPD (LODOT-BCOPD).
RCT Entities:
BACKGROUND:COPD is a leading cause of death globally, with the majority of morbidity and mortality occurring in low- and middle-income country (LMIC) settings. While tobacco-smoke exposure is the most important risk factor for COPD in high-income settings, household air pollution from biomass smoke combustion is a leading risk factor for COPD in LMICs. Despite the high burden of biomass smoke-related COPD, few studies have evaluated the efficacy of pharmacotherapy in this context. Currently recommended inhaler-based therapy for COPD is neither available nor affordable in most resource-limited settings. Low-dose theophylline is an oral, once-a-day therapy, long used in high-income countries (HICs), which has been proposed for the management of COPD in LMICs in the absence of inhaled steroids and/or bronchodilators. The Low-dose Theophylline for the Management of Biomass-Associated COPD (LODOT-BCOPD) trial investigates the clinical efficacy and cost-effectiveness of low-dose theophylline for the management of biomass-related COPD in a low-income setting. METHODS: LODOT-BCOPD is a randomized, double-blind, placebo-controlled trial to test the efficacy of low-dose theophylline in improving respiratory symptoms in 110 participants with moderate to severe COPD in Central Uganda. The inclusion criteria are as follows: (1) age 40 to 80 years, (2) full-time resident of the study area, (3) daily biomass exposure, (4) post-bronchodilator FEV1/FVC below the 5th percentile of the Global Lung Initiative mixed ethnic reference population, and (5) GOLD Grade B-D COPD. Participants will be randomly assigned to receive once daily low-dose theophylline (200 mg ER, Unicontin-E) or placebo for 52 weeks. All participants will receive education about self-management of COPD and rescue salbutamol inhalers. We will measure health status using the St. George's Respiratory Questionnaire (SGRQ) and quality of life using the EuroQol-5D (EQ-5D) at baseline and every 6 months. In addition, we will assess household air pollution levels, serum inflammatory biomarkers (fibrinogen, hs-CRP), and theophylline levels at baseline, 1 month, and 6 months. The primary outcome is change in SGRQ score at 12 months. Lastly, we will assess the cost-effectiveness of the intervention by calculating quality-adjusted life years (QALYs) from the EQ-5D. TRIAL REGISTRATION: ClinicalTrials.gov NCT03984188 . Registered on June 12, 2019 TRIAL ACRONYM: Low-dose Theophylline for the Management of Biomass-Associated COPD (LODOT-BCOPD).
Authors: W C Tan; D D Sin; J Bourbeau; P Hernandez; K R Chapman; R Cowie; J M FitzGerald; D D Marciniuk; F Maltais; A S Buist; J Road; J C Hogg; M Kirby; H Coxson; C Hague; J Leipsic; D E O'Donnell; S D Aaron Journal: Thorax Date: 2015-06-05 Impact factor: 9.139
Authors: Chundak T Sherpa; Steven L LeClerq; Shakuntala Singh; Neha Naithani; Raju Pangeni; Arjun Karki; Ramesh K Chokhani; MeiLan Han; Margaret Gyetko; James M Tielsch; William Checkley Journal: Chronic Obstr Pulm Dis Date: 2015-09-02
Authors: Nicole M Robertson; Emily M Nagourney; Suzanne L Pollard; Trishul Siddharthan; Robert Kalyesubula; Pamela J Surkan; John R Hurst; William Checkley; Bruce J Kirenga Journal: Chronic Obstr Pulm Dis Date: 2019-01-04
Authors: John L Hankinson; Steven M Kawut; Eyal Shahar; Lewis J Smith; Karen Hinckley Stukovsky; R Graham Barr Journal: Chest Date: 2009-09-09 Impact factor: 9.410
Authors: Graham Devereux; Seonaidh Cotton; Peter Barnes; Andrew Briggs; Graham Burns; Rekha Chaudhuri; Henry Chrystyn; Lisa Davies; Anthony De Soyza; Shona Fielding; Simon Gompertz; John Haughney; Amanda J Lee; Kirsty McCormack; Gladys McPherson; Alyn Morice; John Norrie; Anita Sullivan; Andrew Wilson; David Price Journal: Trials Date: 2015-06-10 Impact factor: 2.279
Authors: Sophie Bonjour; Heather Adair-Rohani; Jennyfer Wolf; Nigel G Bruce; Sumi Mehta; Annette Prüss-Ustün; Maureen Lahiff; Eva A Rehfuess; Vinod Mishra; Kirk R Smith Journal: Environ Health Perspect Date: 2013-05-03 Impact factor: 9.031
Authors: Brooks W Morgan; Matthew R Grigsby; Trishul Siddharthan; Robert Kalyesubula; Robert A Wise; John R Hurst; Bruce Kirenga; William Checkley Journal: BMJ Open Respir Res Date: 2018-07-11